32
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Long‐Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer‐Generation Drug‐Eluting Stents

      research-article
      , MD, PhD 1 , , MD 1 , , MD 1 , , MD, PhD 1 , , PhD 1 , , MD, PhD 2 , , MD, PhD 1 , , MD, PhD 1 , , MD, PhD 1 , , MD 1 , , MD 1 , , MD, PhD 3 , , PhD 4 , , MD, PhD 2 , , MD, PhD 1 , 4 ,
      Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
      John Wiley and Sons Inc.
      coronary artery bypass graft, drug‐eluting stent, percutaneous coronary intervention, Resolute, Xience V, Cardiovascular Surgery, Percutaneous Coronary Intervention, Revascularization

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Percutaneous coronary intervention ( PCI) in patients with previous coronary artery bypass grafting ( CABG) is associated with adverse clinical events. Although newer generation drug‐eluting stents showed favorable short‐term safety profiles, there is a lack of long‐term outcome data. We evaluated the impact of previous CABG on 5‐year clinical outcomes of patients treated with PCI using newer‐generation drug‐eluting stents.

          Methods and Results

          In this patient‐level pooled analysis of the prospective TWENTE (The Real‐World Endeavor Resolute versus Xience V Drug‐Eluting Stent Study in Twente) trial and nonenrolled TWENTE registry, we assessed a consecutive series of patients who underwent PCI with newer‐generation drug‐eluting stents for non– ST‐segment–elevation acute coronary syndromes or stable angina. Of all 1709 patients, 202 (11.8%) had a history of CABG. Patients with previous CABG had significantly higher 5‐year rates of cardiac death (10.4% versus 4.3%; P<0.001) and target vessel revascularization (25.0% versus 8.1%; P<0.001). These differences remained statistically significant after adjustment for differences in baseline characteristics. Landmark analysis revealed that from 1‐ to 5‐year follow‐up, the rates of cardiac death (8.1% versus 3.2%; P<0.001) and target vessel revascularization (17.1% versus 5.9%; P<0.001) were significantly higher in patients with previous CABG. Among patients with a history of CABG, PCI of an obstructed vein graft was associated with a higher rate of 5‐year target vessel revascularization ( P=0.003).

          Conclusions

          At 5‐year follow‐up after PCI with newer‐generation drug‐eluting stents, the risk of cardiac death and target vessel revascularization was significantly higher in patients with previous CABG. The target vessel revascularization rate was highest in patients who underwent PCI of obstructed vein grafts.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial

          In patients with coronary artery disease, treated with durable polymer-coated drug-eluting stents, the life-long presence of the polymer might delay arterial healing. Novel very thin strut biodegradable polymer stents, which leave only a bare metal stent after polymer resorption, might improve long-term outcome. We investigated in allcomers the safety and efficacy of three stents eluting either everolimus, sirolimus, or zotarolimus, often clinically used but never compared, of which the biodegradable polymer everolimus-eluting stent was never before assessed in allcomers.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial

              Comparative assessment of clinical outcomes after use of drug-eluting stents versus bare-metal stents for treatment of aortocoronary saphenous vein graft lesions has not been undertaken in large randomised trials. We aimed to undertake a comparison in a randomised trial powered for clinical endpoints.
                Bookmark

                Author and article information

                Contributors
                c.vonbirgelen@mst.nl
                Journal
                J Am Heart Assoc
                J Am Heart Assoc
                10.1002/(ISSN)2047-9980
                JAH3
                ahaoa
                Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
                John Wiley and Sons Inc. (Hoboken )
                2047-9980
                30 January 2018
                February 2018
                : 7
                : 3 ( doiID: 10.1002/jah3.2018.7.issue-3 )
                : e007212
                Affiliations
                [ 1 ] Department of Cardiology Thoraxcentrum Twente Medisch Spectrum Twente Enschede the Netherlands
                [ 2 ] Department of Cardiothoracic Surgery Thoraxcentrum Twente Medisch Spectrum Twente Enschede the Netherlands
                [ 3 ] Department of Cardiology Ziekenhuisgroep Twente Almelo and Hengelo the Netherlands
                [ 4 ] Department of Health Technology and Services Research MIRA—Institute for Biomedical Technology and Technical Medicine University of Twente Enschede the Netherlands
                Author notes
                [*] [* ] Correspondence to: Clemens von Birgelen, MD, PhD, Thoraxcentrum Twente, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, the Netherlands. E‐mail: c.vonbirgelen@ 123456mst.nl
                Article
                JAH32906
                10.1161/JAHA.117.007212
                5850240
                29382666
                fc1f03db-ba6d-41b2-a942-9c6aec2da6dd
                © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

                This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 21 September 2017
                : 06 December 2017
                Page count
                Figures: 5, Tables: 3, Pages: 13, Words: 6451
                Funding
                Funded by: Abbott Vascular
                Funded by: Medtronic
                Categories
                Original Research
                Original Research
                Epidemiology
                Custom metadata
                2.0
                jah32906
                February 2018
                Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.2.2 mode:remove_FC converted:06.02.2018

                Cardiovascular Medicine
                coronary artery bypass graft,drug‐eluting stent,percutaneous coronary intervention,resolute,xience v,cardiovascular surgery,revascularization

                Comments

                Comment on this article